Clin2
NCT07499440Possibly a fitRecruiting

Testing a new medicine, HB-1, for PTSD

PTSDMental Illness

Part of Mental health clinical trials.

This trial tests an experimental medicine, HB-1, as a potential treatment for PTSD. It is a 8-week study to see if the medicine is safe and if it reduces PTSD symptoms. You must have a stable medication routine and be willing to take the study pill daily.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
200 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have a diagnosis of PTSD confirmed by a mental health professional.
  • Your PTSD symptoms are at least moderately severe (score of 26 or higher on a standard test).
  • Your current medications and therapy have been stable for at least 2 months and you can keep them the same during the trial.
  • You are not currently taking benzodiazepines (like Xanax or Valium) or opioid painkillers (like codeine or morphine).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04452500Recruiting· Phase 2
Study drug for PTSD symptoms in Veterans

This trial tests a study medicine that blocks the effects of cortisol (a stress hormone) to reduce PTSD symptoms in Veterans. It’s meant for people with ongoing PTSD symptoms and stable treatments, and it closely checks safety because the medicine can affect sleep, mood, and heart rhythm.

Tuscaloosa, Alabama
NCT07704762Not yet recruiting· Phase 2
MDMA-assisted therapy for PTSD in military members

This trial tests if MDMA (a drug that can help with therapy) along with talk therapy can help military members with PTSD. It is designed for active duty, National Guard, or Reserve service members who have had PTSD for at least six months.

NCT05746572Enrolling by invitation· Phase 2
MDMA-assisted therapy plus exposure therapy for PTSD

This Phase 2 study tests whether MDMA combined with therapy that uses exposure (gradual confronting of trauma memories) can reduce PTSD symptoms. It may help people who meet PTSD criteria, can follow strict safety rules, and can complete medicine-session monitoring.

Atlanta, Georgia
NCT06902974Recruiting· Phase 2
Psilocybin therapy for PTSD from sexual assault

This trial tests whether psilocybin, a psychedelic drug given in a supportive therapy setting, can help women heal from post-traumatic stress disorder (PTSD) caused by a sexual assault that happened 6 or more months ago. You'll receive the drug during supervised sessions and attend therapy visits to see if it reduces your PTSD symptoms.

Rockville, Maryland
NCT07506395Recruiting· Phase 1
Psilocybin group therapy for PTSD

This study tests if psilocybin-assisted group therapy can help people with moderate to severe PTSD. It is for veterans, first responders, female survivors of sexual violence, or Indigenous individuals.

Albuquerque, New Mexico
NCT07664631Not yet recruiting· Phase 1
Testing stimulant medications for PTSD

This study tests whether stimulant medications can help treat PTSD symptoms. Researchers want to see if these medications are safe and effective for people with PTSD.

Chicago, Illinois

Hear when a new Mental Illness trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.